title: Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial.
abstract: BACKGROUND
  Nutritional interventions have shown increased energy intake but not improvement in health-related quality of life (HRQL) or prognosis in non small cell lung cancer (NSCLC) patients. Eicosapentaenoic acid has been proposed to have anti-inflammatory, anticachectic and antitumoural effects.
  
  
  OBJECTIVE
  To compare the effect of an oral EPA enriched supplement with an isocaloric diet on nutritional, clinical and inflammatory parameters and HRQL in advanced NSCLC patients.
  
  
  METHODS
  Patients with advanced NSCLC were randomized to receive diet plus oral nutritional supplement containing EPA (ONS-EPA) or only isocaloric diet (C). All patients received paclitaxel and cisplatin/carboplatin treatment. Weight, body composition, dietary intake, inflammatory parameters and HRQL were assessed at baseline and after the first and second cycles of chemotherapy. Response to chemotherapy and survival were evaluated.
  
  
  RESULTS
  Ninety two patients were analysed (46 ONS-EPA,46 C). ONS-EPA group had significantly greater energy (p < 0.001) and protein (p < 0.001) intake compared with control. Compared with baseline, patients receiving the ONS-EPA gained 1.6 ± 5 kg of lean body mass (LBM) compared with a loss of -2.0 ± 6 kg in the control (p = 0.01). Fatigue, loss of appetite and neuropathy decreased in the ONS-EPA group (p ≤ 0.05). There was no difference in response rate or overall survival between groups.
  
  
  CONCLUSIONS
  Patients with NSCLC receiving ONS-EPA significantly improves energy and protein intake, body composition. and decreased fatigue, loss of appetite and neuropathy. Registered with ClinicalTrials.gov (NCT01048970).
authors.affiliation: Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.
authors.forename: Karla
authors.initials: K
authors.lastname: Sánchez-Lara
authors.affiliation: Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.
authors.forename: Jenny G
authors.initials: JG
authors.lastname: Turcott
authors.affiliation: Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.
authors.forename: Eva
authors.initials: E
authors.lastname: Juárez-Hernández
authors.affiliation: Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.
authors.forename: Carolina
authors.initials: C
authors.lastname: Nuñez-Valencia
authors.affiliation: Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.
authors.forename: Geraldine
authors.initials: G
authors.lastname: Villanueva
authors.affiliation: Neuroimmunology Unit/Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
authors.forename: Patricia
authors.initials: P
authors.lastname: Guevara
authors.affiliation: Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.
authors.forename: Martha
authors.initials: M
authors.lastname: De la Torre-Vallejo
authors.affiliation: Cancer Research Unit/Instituto Nacional de Cancerología, Mexico City, Mexico.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Mohar
authors.affiliation: Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico; Universidad Nacional Autónoma de México, Mexico City, Mexico. Electronic address: ogar@servidor.unam.mx.
authors.forename: Oscar
authors.initials: O
authors.lastname: Arrieta
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001066:Appetite / Q000187:drug effects; D001823:Body Composition / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D016190:Carboplatin / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use; D019587:Dietary Supplements; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage*; D002149:Energy Intake; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status; D011379:Prognosis; D011788:Quality of Life; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D015118:Eicosapentaenoic Acid; D016190:Carboplatin; D002945:Cisplatin
keywords: Eicosapentaenoic acid; Health-related quality of life; Non-small cell lung cancer; Nutritional status